An early appreciation of treatment efficacy could be very useful in acute myeloblastic leukemia (AML), and a prognostic value has been suggested for the morphological assessment of decrease in blasts during induction therapy. More sensitive, multiparametric flow cytometry (FCM) can detect far lower blast counts, allowing for a precise and reliable calculation of blast cell decrease rate (BDR). Such a multiparametric FCM fourcolours/single-tube protocol, combining CD11b, CD45-ECD and CD16-PC5, was applied to peripheral blood samples from 130 AML patients, collected daily during induction chemotherapy. Normalized blast cell percentages were used to calculate the relevant decrease slopes. Slope thresholds (oÀ25, À25 to À15 and 4À15), or the time required to reach 90% depletion of the peripheral blast load (o5, 5 or 45 days), was strongly associated with the achievement of complete remission (Po0.0001). Log-rank test and Cox model showed that they also carried high statistical significance (Po0.0001) for disease-free survival. The prognostic value of cytogenetic features, confirmed in this series, was refined by BDR, which allowed to discriminate between good-and poor-risk patients among those with intermediate or normal karyotypes. This simple FCM protocol allows for an accurate prognostic sequential approach adapted to the determination of decrease in peripheral blast cells during induction chemotherapy.
Introduction
In spite of the progress of therapeutic approaches in the past few decades, the prognosis of acute myeloblastic leukemia (AML) remains unsatisfactory.
1,2 Progress of diagnostic methods, that is, morphology, cytogenetics, immunophenotyping and molecular biology has led to the identification of prognosis factors [3] [4] [5] and has helped to better stratify patients. 6 Nevertheless, it is difficult to properly appreciate the efficacy of induction therapy before the first informative examination of bone marrow smears. Yet, for some of the patients who do not achieve complete remission (CR) after the first cycle of chemotherapy, prognosis has been reported to be poorer. [7] [8] [9] In the early 1990s, a pathophysiologic model of the evolution of leukemia under chemotherapy was developed by Browman and Preisler, 10 showing that the rate of decrease of morphologically identified medullary blasts during induction therapy could constitute an important prognostic indicator. This hypothesis, although elegant, was, however, not pushed further, mostly because repeated bone marrow aspirations were difficult to implement for practical reasons and because precise counts of bone marrow blast cells are extremely difficult to perform by morphological examination.
Increasing sophistication of the technology of flow cytometry (FCM) has, in recent years, considerably improved the sensitivity of this method, and a combination of two morphological signals (forward and side scatter) and four fluorochromes labelling allows for a theoretical detection sensitivity of 10 À5 events. 11 Such levels of detection allow to envision the possibility of tracking extremely rare events, such as residual blasts in peripheral blood (PB) samples. 12 Indeed, recent data suggest that the detection of minimal residual disease by FCM could be successfully applied in the early times of chemotherapy to bone marrow. 13 By extension, the possibility of sequentially evaluating PB blast cells during induction chemotherapy could constitute an interesting alternative.
Here, we propose such a one-step FCM protocol allowing to reliably identify all mature white blood cell (WBC) compartments in whole PB samples, and, by use of a subtractive approach, to isolate a region of interest normally devoid of any cell but occupied by blast cells in leukemic patients. Sequential determination of the percentage of PB blasts in this normally 'empty space' allows to monitor blast cell decrease (BDR), a new feature that was correlated to the clinical evolution of 130 AML patients and other classical prognostic factors.
Materials and methods

Patients
One hundred and thirty patients were enroled in this study, in three university hospitals (Bordeaux, Nancy and Dijon) and one cancer centre (Marseille). All those who suffered from non-M3 AML were enroled in one of the GOELAMS's clinical trials, LAM2001 or LAMSA02, 14, 15 or treated accordingly, and had provided informed consent. LAM2001 was devised for patients lesser than 60 years of age and compared the efficacy of idarubicin (8 mg/m 2 /d, 5 days) or daunorubicin (60 mg/m 2 /d, 3 days) and high-dose cytarabine (200 mg/m 2 /d, 7 days). On examination of a bone marrow aspiration at day 15, patients received or not a second induction chemotherapy, depending on the persistence of more than 5% blasts or Auer rods. Patients over 60 years of age were entered in the LAMSA02 trial, which used a comparable induction therapy of idarubicin (8 mg/m 2 /day, 5 days) and cytarabine (100 mg/m 2 /day, 7 days), associated with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (one take of 200 mg/m 2 ) and G-CSF from day 8 on. PB samples were obtained from the catheter and collected on EDTA-K on a daily basis from the first day (D1) of induction chemotherapy, until at least day 7. WBC counts were collected at each time point. Characteristics of the patients are summarized in Table 1 . At day D0 of treatment, for all PB samples, WBC ranged between 0.5 and 355 G/L and blast cells between 3.1 and 97.8% of leukocytes.
CR and relapse were appreciated on bone marrow samples by morphological examination according to standard criteria. 16 
Flow cytometry
A mixture of four monoclonal antibodies was prepared extemporaneously before each test. It comprised the following conjugates: CD14-FITC, CD11b-PE, CD45-ECD and CD16-PC5 (Beckman Coulter, Miami, FL, USA).
At each time point, 50 ml of PB was incubated with the antibody mix for 15 min in the dark after gentle vortexing. The samples were then lysed using Versalyse (Beckman Coulter, Bordeaux, France), Immunoprep (Beckman Coulter, Nancy, France) or BDFACSLysis (BD Biosciences (Franklin Lakes, NJ, USA, Dijon, France, and Marseille, France) and immediately processed in FCM.
Events were collected for 300 s or until at least 100 000 events had been acquired. All list modes were saved for further analysis according to the method described in Figure 1 legend. This gating strategy allowed to positively identify monocytes
. [17] [18] [19] A subtractive strategy then allowed to evidence peripheral blast cells.
BDR assessment
For each patient, three parameters were recorded at each time point of PB collection: (i) blast cell percentage among leukocytes, (ii) WBC, (iii) calculated absolute blast cell numbers. Data were tabulated on an Excel (Microsoft Corporation) matrix. To compare results, data normalization was performed by attributing a value of 100 to D0 parameters and subsequently adjusting all data (Figure 1) .
BDR was evaluated using blast cell percentages and absolute numbers; yet more significant results were obtained using the former (data not shown). For BDR evaluation, two points were considered: D0 and D90%, the latter being the first day when at least 90% of the initial blast load had disappeared from PB. BDR was evaluated using two modalities: (a) calculation of the blast cell decrease slope by linear regression between D0 and D90% and (b) determination of the time lapse to reach D90%, further dubbed BDR90. An example of slope calculation is given in Figure 2a from the data shown in Figure 1 .
Slope analysis and BDR90 calculation are compared in Figure 2b . This shows an excellent correlation between these two means of BDR assessment (r ¼ 0.913). BDR90 could be easier to use for clinical considerations.
Cytogenetics
Karyotypic information was collected in each centre, reviewed by EL and IL, and finally considered available for 118 patients. Karyotypes, classified into three categories as described elsewhere, 20 were of favourable risk (t(8;21) or inv(16)) for 13 patients, unfavourable (complex karyotype or inv(3) or t(6;9) or t(6;11) or t (11;19) Abbreviations: CR, complete remission; WBC, white blood cells; PB, peripheral blood; BDR, blast cell decrease rate.
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Statistical analysis
Descriptive statistics, including proportions, means, standard deviations and medians, were used to analyze parameter distributions within subgroups. Patients' characteristics and CR rate comparisons were performed using two-sided Fisher's exact test or w 2 test for categorical variables. Mean comparisons were performed using t-test after F-test verification of equal variance and the Mann-Whitney test for median comparisons.
Pearson's correlation coefficient was used to evaluate the correlation between paired values of BDRslope and BDR90. Slopes were compared between patients who failed to reach remission, relapsed or remained in CR, using two-way analysis of variance.
Logistic regression was used to evaluate the relationship between the results of induction (CR or not) and clinico-biological parameters. All variables were simultaneously entered into the model to check their respective contribution to the outcome.
Disease-free survival (DFS) was calculated from the date of CR achievement until first relapse or death in CR, and patients alive in CR were censored at the last known information. Eventfree survival (EFS) was calculated from the date of initial treatment until first relapse or death, and patients alive in CR were censored at the last known information. DFS and EFS were estimated by the Kaplan-Meier method 21 and compared using the log-rank test 22 or log-rank test for linear trend in the case of ordered categorical variables (BDRslope and BDR90). Blast cell decrease in AML as a prognostic factor F Lacombe et al Thresholds used in statistical analyses were those that maximized the differences in statistical tests and were carefully chosen by examining raw data.
A multiparametric analysis of prognosis was performed using Cox's proportional hazard model. 23 All variables were first added and sequentially deleted at P40.05.
All statistical computations were performed using the Medcalc software (Mariakerke, Belgium).
Results
Patients' outcome
Of the 130 patients, 111 (85.4%) reached CR, among whom 47 (36.2%) relapsed. CR was obtained with one round of induction chemotherapy for 76% of the patients enroled in the LAM2001 trial. In all 19 (14.6%) patients failed to reach CR. Median follow-up was 347 (max 1250) days at updating. Consequently, three groups could be constituted (Table 1) : (1) patients achieving CR without relapse in the course of the follow-up period (n ¼ 64), (2) patients relapsing after achieving CR (n ¼ 47) and (3) patients failing to achieve CR (n ¼ 19). Median CR durations were of 610 and 176 days, respectively, for patients in groups 1 and 2.
No significant difference was observed between these three groups for sex, age, WBC and PB blast percentages. Conversely, BDR was significantly different between the three groups using BDRslope (Po0.0001) or BDR90 (Po0.0001) (Figures 2c and  d) . Similarly, the frequency of favourable, intermediate and unfavourable karyotypes was significantly different within the three groups (Po0.0001).
Four patients in group 3 died during induction therapy and had a very bad BDRslope (À3.25 ± 3.67) compared with the other 15 patients of group 3 who completed induction (À8.72 ± 4.34).
CR achievement
Among the two clinical (sex, age) and four biological (WBC, PB blast %, karyotype, BDR) parameters summarized in Using either slope or BDR90, BDR was the other major parameter determining CR achievement. Thus, all patients with BDR90 o6 (n ¼ 81) achieved CR, whereas 19/49 (38.8%) patients with BDR90 45 did not achieve CR (Po0.0001). 
Survival analysis
Considering either relapse onset or patient's death as events, two EFS curves are shown in Figures 3a and b according to BDRslope or BDR90, respectively. Log-rank comparisons were established according to the threshold values identified for the three groups shown in Figures 2c and d (that is, oÀ25 , between À25 and À15, 4À15 for BDRslope and oday 5, ¼ day 5 and 4 day 5 for BDR90). Blast cell decrease in AML as a prognostic factor F Lacombe et al
Once CR is achieved, a major component of AML prognosis is CR duration or DFS analysis. There was no difference in DFS among patients aged over 60 years enroled in LAMSA02 or treated accordingly. Similarly, younger patients enroled in LAM2001 or treated accordingly had similar DFS. Moreover, the discriminative powers of BDRslope and BDR90 were similar whatever the age group (data not shown).
Only three parameters were found to significantly contribute to DFS length in this series: age, karyotype and BDR. DFS curves are not shown for nonsignificant parameters, that is, sex, WBC and PB blast percentage.
Although age did not significantly influence CR achievement, it was found to contribute to DFS duration, 65 years of age being the best statistical threshold (Figure 3a , Po0.005).
Earlier described as a significant parameter for CR achievement, karyotype was also an important parameter for predicting DFS length. Taking into account the three classical karyotypic prognostic factors, three different DFS curves could be derived. Their comparison was highly significant by the log-rank test (Po0.0001) and log-rank for linear trend (Po0.0001) (Figure 3b) . BDR, earlier observed as the major parameter determining CR achievement, is also the major factor for discriminating between different DFS groups. Considering BDRslope, three groups could be created to maximize differences in DFS: with slope oÀ25, between À25 and À15 and slope 4À15. Considering BDR90, three groups could also be created in the same way with BDR90 o5 days, BDR90 ¼ 5 days and BDR90 45 days. Whatever the modality of BDR analysis chosen (slope or BDR90), three groups with clearly different DFS curves could be isolated with a high degree of significance (Po0.0001Flog-rank and Po0.0001Flog-rank for linear trend) as shown in Figures 3c and d (Figure 4a ). Yet, BDR assessment allowed to override this discrepancy and observe patients with unfavourable intermediate and favourable BDR, both for normal and for intermediate karyotypes (Po0.0001) (Figures 4b and c) .
As for CR achievement analysis, two clinical (sex, age) and four biological (WBC, PB blast %, karyotype, BDR) parameters were tested in a multiparametric analysis using a Cox model. Only two covariables were retained as influencing EFS (karyotype (Po0.05) and BDR (Po0.0001)) and DFS (karyotype (Po0.01) and BDR (Po0.0001)).
Discussion
This study reports on a robust and simple FCM assay allowing to accurately appreciate the percentage of peripheral blast cells in patients with AML during the first days of induction therapy. This tool appears to be reliable, as long as a careful analysis of list modes is performed, with an accurate definition of mature WBC, isolating a 'negative' gate containing the blast population. The presence of blast cells in the earliest samples, moreover, provides a good positive control to then track the decreasing blast cell population. Calculation of the decrease rate of peripheral blast percentages after normalization of the data allows to directly appreciate the chemosensitivity of individual patients.
PB BDR assessment is more reliable and easy to interpret than the traditional morphological examination of medullary blast cells, especially when their levels are around the threshold value in aplastic bone marrow. 10 Moreover, by being performed on sequential PB samples, BDR appreciation is more accurate than a single examination. This FCM approach is also more objective Blast cell decrease in AML as a prognostic factor F Lacombe et al and systematic than that recently reported using morphological examination of blood smears, 24 although it reaches similar conclusions. The great difference between this study and our study is that our initial blast counts were as low as 3%. As shown in the example here, the level of detection can accurately go as low as 10 À3 or 10 À4 during induction chemotherapy in PB samples, a feature making it applicable also to older patients with low peripheral blastosis. Moreover, it seems statistically impossible to appreciate a blast cell decrease by morphology if the initial blast percentage is o10% (see the classical Rü mke table 25 ). From a practical point of view, this assay makes use of the robust FCM definition of mature leukocytes, which is independent of morphological alterations liable to incur owing to the ongoing infusion of cytotoxic drugs. By relying on a positive identification of normal cells, it levers the subjective interpretation of atypical immunophenotypes exhibited by AML cells, which is moreover patient-specific. Therefore, this assay is applicable whatever the initial immunophenotype of the blasts, with the provision of CD11b þ cases, where the CD16/CD11b scattergram used to track blast cell decrease must be adapted.
This new tool appears to be very useful clinically for an early and accurate appreciation of individual patients' behaviour during the first stages of chemotherapy, possibly allowing to better adapt to therapeutic strategies. This usefulness is shown by the highly significant discrimination observed when comparing BDR for patients who did or did not reach CR. Therefore, BDR provides a rapid and kinetic approach of individual patients' chemosensitivity at the very early stage of the first days of induction therapy. Extension of this approach could lead to devise new strategies for the stratification of consolidation therapy.
A second interest of BDR assessment is its strong prognostic value even of remission duration, with highly significant different outcomes based on either BDRslope or BDR90, and early relapses for the patients with the worst BDR. This suggests that an early decrease of the tumoral load may have an impact on the efficacy of further consolidation therapies. Again, this observation could lead to modify the therapeutic management of AML patients, including the decision of allogeneic stem cell transplantation.
A third interesting feature of BDR is its value as an independent prognostic factor, considering BDR measurement using blast percentages. It was proved that WBC decrease rate was not a significant prognosis factor and consequently BDR measurement using absolute blast count was not so good a prognostic factor than BDR measurement using blast percentages (data not shown). Moreover, BDR provides additional information to karyotypic features. Indeed, among the various parameters considered to be of prognostic value in AML, karyotypic investigations have been the focus of many studies, resulting in precise definitions of anomalies of favourable and unfavourable prognosis. [25] [26] [27] [28] Outside of these two groups, patients are considered to be of 'intermediate' prognosis. Interestingly, blast cell sensitivity to chemotherapy as assessed here brings further prognostic value within this group of patients. As BDR during the first days of chemotherapy is likely to yield results slightly before complete karyotypic investigations are completed, a combined use of these two sets of information could bring a novel and highly useful means for treatment stratification. In a prospective study, it would be of great interest to analyze the prognostic impact of the more recently described molecular markers in comparison with cytogenetics and BDR.
Finally, performed in four different settings with different equipment, our work already suggests that excellent reproducibility can be achieved in various laboratories. By applying this strategy to the samples obtained nevertheless for WBC counts, this one-combination FCM test could rapidly confirm its value.
In conclusion, we propose a simple, robust, specific and clinically useful method allowing to rapidly appreciate chemosensitivity in the early stages of chemotherapy for patients with AML. The strong correlation of blast cell decrease slopes and patients' outcome, if confirmed in larger scale studies, could make this test a new standard for therapeutic stratification in this disease, even in patients with intermediate cytogenetic features.
